GRAIL (NASDAQ:GRAL) Trading Down 6.2% – What’s Next?

GRAIL, Inc. (NASDAQ:GRALGet Free Report)’s stock price fell 6.2% during trading on Friday . The stock traded as low as $45.60 and last traded at $45.44. 721,583 shares changed hands during trading, a decline of 43% from the average session volume of 1,262,627 shares. The stock had previously closed at $48.44.

Analysts Set New Price Targets

Several brokerages recently commented on GRAL. Morgan Stanley raised their target price on GRAIL from $16.00 to $20.00 and gave the company an “equal weight” rating in a report on Tuesday, March 18th. Canaccord Genuity Group raised their price objective on GRAIL from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th.

View Our Latest Stock Analysis on GRAIL

GRAIL Trading Down 5.8%

The business has a 50 day simple moving average of $37.25 and a two-hundred day simple moving average of $31.02. The stock has a market cap of $1.64 billion and a price-to-earnings ratio of -0.75.

GRAIL (NASDAQ:GRALGet Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($3.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.93. GRAIL had a negative return on equity of 17.99% and a negative net margin of 1,464.53%. The firm had revenue of $31.84 million during the quarter, compared to analyst estimates of $35.80 million. Research analysts anticipate that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Insider Buying and Selling at GRAIL

In other GRAIL news, CFO Aaron Freidin sold 41,150 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $33.93, for a total transaction of $1,396,219.50. Following the transaction, the chief financial officer now owns 294,020 shares of the company’s stock, valued at $9,976,098.60. This trade represents a 12.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Joshua J. Ofman sold 48,213 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $33.93, for a total value of $1,635,867.09. Following the transaction, the president now directly owns 511,460 shares in the company, valued at approximately $17,353,837.80. This represents a 8.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 183,398 shares of company stock worth $6,222,694 in the last 90 days. 1.85% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. S.A. Mason LLC lifted its holdings in GRAIL by 50.1% during the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company’s stock worth $38,000 after buying an additional 500 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of GRAIL by 28.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares during the last quarter. HighTower Advisors LLC lifted its holdings in shares of GRAIL by 5.7% in the 1st quarter. HighTower Advisors LLC now owns 11,591 shares of the company’s stock worth $296,000 after purchasing an additional 627 shares during the last quarter. KBC Group NV lifted its holdings in shares of GRAIL by 187.7% in the 1st quarter. KBC Group NV now owns 1,430 shares of the company’s stock worth $37,000 after purchasing an additional 933 shares during the last quarter. Finally, Caldwell Sutter Capital Inc. bought a new stake in shares of GRAIL in the 1st quarter worth approximately $28,000.

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

Featured Stories

Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.